Puma Biotechnology, Inc.
Puma Biotechnology, Inc. (PBYI) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
pbyi · stock forecast · 19 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 19 Wall Street analysts in the past 3 months
Buy
19 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $6.85
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $6.77 | ↓ 1.16% |
1-day model range: $6.75–$6.79. Peak: $6.79 (-1.16%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $8 | +20.9% |
| 2028 | $9 | +34.8% |
| 2029 | $10 | +43.3% |
| 2030 | $10 | +48.2% |
| 2031 | — | +51.1% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · PBYI · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-02-28 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-12-23 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-11-20 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-11-08 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-08-02 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-07-26 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-06-04 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-06-03 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-05-20 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-05-03 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Puma Biotechnology, Inc. (PBYI) stock. Of the recent 89 rating actions, 6 were upgrades and 11 were downgrades. 19 analysts currently cover PBYI.
Analyst Recommendation Trends
PBYI analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$222M
↑ 2.8% YoY
Revenue Next Year
$219M
↓ 1.4% YoY
EPS This Year
$0.29
EPS Next Year
$0.20
↓ 31.0% YoY
EPS ForecastReported vs Estimated
Analysts forecast PBYI EPS of $0.29 for the current fiscal year, based on estimates from 1 analysts. The PBYI revenue forecast is $222M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The PBYI stock forecast is supported by two independent data sources: analyst consensus ratings from 19 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus PBYI price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The PBYI short-term stock prediction for tomorrow is $6.77 (-1.16%). The PBYI stock price prediction for 2027 estimates an average of $8. The PBYI stock prediction for 2030 projects a range of $10–$11.
Puma Biotechnology, Inc. trades on NASDAQ under the ticker PBYI. The PBYI stock outlook for 2027 is broadly positive, supported by a Buy consensus among 42% of covering analysts.
Frequently asked questions
PBYI forecast · 8 questionsAccording to 19 Wall Street analysts, the average 12-month PBYI price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $6.85.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.